New hope for teens with rare tumors: lutathera safety trial underway

NCT ID NCT04711135

First seen Feb 13, 2026 · Last updated May 15, 2026 · Updated 11 times

Summary

This study tests a radioactive drug called Lutathera in teenagers aged 12 to 18 who have rare tumors of the gut, pancreas, or nerve tissue. The goal is to check how safe the drug is and how much radiation reaches organs like the kidneys and bone marrow. About 11 participants will receive the treatment and be monitored for side effects. This is not a cure, but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Léon Berard

    Lyon, France

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Cincinnati Children's Hospital

    Cincinnati, Ohio, 45229-3039, United States

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Gliwice, Poland

  • University College Hospital of London

    London, United Kingdom

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

Conditions

Explore the condition pages connected to this study.